The present invention provides conformationally restricted 4-substituted 2,6-dimethylfuro[2,3-d]pyrimidine compounds and pharmaceutical compositions comprising these compounds. Preferably, the compounds exhibit dual inhibition of microtubule assembly and receptor tyrosine kinases. Methods of treating cancer comprising administering a therapeutically effective amount of at least one conformationally restricted 4-substituted 2,6-dimethylfuro[2,3-d]pyrimidine compound to a patient is disclosed.
本发明提供构象限制的4-取代2,6-二甲基
呋喃[2,3-d]
嘧啶化合物和包含这些化合物的制药组合物。优选地,这些化合物表现出微管组装和受体
酪氨酸激酶的双重抑制作用。本发明还公开了治疗癌症的方法,包括向患者施用至少一种构象限制的4-取代2,6-二甲基
呋喃[2,3-d]
嘧啶化合物的治疗有效剂量。